New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
06:42 EDTHLF, TEVAStocks with implied volatility movement; TEVA HLF
Stocks with implied volatility movement; Teva (TEVA) 28, Herbalife (HLF) 81 according to iVolatility.
News For TEVA;HLF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 24, 2015
07:07 EDTHLFHerbalife plans PR campaign to hit back at Ackman, CNBC reports
Subscribe for More Information
06:22 EDTTEVATeva appointment shows transformative M&A not off table, says Citigroup
Subscribe for More Information
March 23, 2015
16:01 EDTTEVAOptions Update; March 23, 2015
iPath S&P 500 VIX Short-Term Futures down 48c to 25.24 Option volume leaders: AAPL TSLA TWTR GILD CELG FB TSLA AMZN TEVA PBR according to Track Data.
12:10 EDTTEVATeva migraine drug data positive for Amgen, says Piper Jaffray
Piper Jaffray said the "positive" trial data Teva (TEVA) reported for its anti-CGRP antibody in migraines is another important validation for the class of drugs that is also being worked on by Amgen (AMGN), Eli Lilly (LLY) and Alder Biopharmaceuticals (ALDR). The firm said it thinks Amgen is one of the leaders in CGRP antibody space and reiterated its Overweight rating and $187 price target on Amgen shares.
11:26 EDTHLFHerbalife rallies, retraces, levels to watch
The shares hit an intraday high at $48.55 and have since turned lower. At the last price of $46.04, support is at $45.11 and then at $44.11, a prior pivot high. Resistance is at $46.24.
10:53 EDTHLFHerbalife continues recent strength with 10% jump
Shares of multi-level marketing company Herbalife (HLF) were up about 10% in morning trading after being up as much as 15% to $48.55 earlier this morning. On March 16, a judge in the U.S. District Court for the Central District of California granted Herbalife its motion to dismiss a class action complaint brought on behalf of shareholders who allege that the company and its executives violated federal securities laws by misrepresenting the "nature, scope and legality" of the company's business and operations. On March 20, Pershing Square, which noted that Bill Ackman and the firm were not parties to the Awad case decided the prior week, said the courtís decision "did not address in any way whether Herbalife is an illegal pyramid scheme, nor did the Court exonerate or bless Herbalifeís business practices." Since March 16, Herbalife shares are up about 29%.
10:14 EDTHLFHerbalife volatility elevated on sharp rally
Subscribe for More Information
08:50 EDTTEVATeva reports TEV-48125 met endpoints in phase 2b study
Subscribe for More Information
March 20, 2015
15:45 EDTHLFHerbalife breaks above top of recent range, levels to watch
Shares have broken out of the top of the recent trading range at $40. This is bullish price behavior. At the current price of $40.79 next resistance is at $42. Support is at $40. It would be bearish for price if the stock resumes trading below the $40 area.
15:38 EDTHLFHerbalife volatility stays elevated on sharp rally
Subscribe for More Information
13:50 EDTHLFPershing Square corrects inaccurate press reports regarding Herbalife
Subscribe for More Information
March 19, 2015
11:02 EDTHLFOptions with increasing implied volatility
Options with increasing implied volatility: HLF RAD NFLX HLSS NOW
March 18, 2015
16:13 EDTTEVAFibrocell Science appoints Keith Goldan as CFO
Fibrocell Science announced the appointment of Keith Goldan as senior VP and Chief Financial Officer, effective immediately. Prior to joining Fibrocell, Goldan served as CFO of two publicly traded companies. Most recently he served as SVP and CFO of NuPathe, which was acquired by Teva Pharmaceutical (TEVA) in 2014.
13:49 EDTHLFHerbalife says 'confident in strong fundamentals of business model'
Subscribe for More Information
11:36 EDTTEVAIgnyta price target raised to $17 from $14 at Leerink
Subscribe for More Information
10:08 EDTTEVAEagle Pharmaceuticals price target increased to $67 from $43 at William Blair
William Blair raised its price target on Eagle Pharmaceuticals to $67 from $43 citing its belief that the company can become profitable and have significant cash flow pending the approval of EP-3102. The company added that it view last week's FDA label change for Teva's (TEVA) Treanda as a positive for EP-3102 and that its new price target assumes 2016 launch and "reasonable" penetration for EP-3102.
09:23 EDTHLFOn The Fly: Pre-market Movers
Subscribe for More Information
08:02 EDTHLFHerbalife wins dismissal of class action 'pyramid scheme' lawsuit
On March 16, a judge in the U.S. District Court for the Central District of California granted Herbalife its motion to dismiss a class action complaint brought on behalf of shareholders who allege that the company and its executives violated federal securities laws by misrepresenting the "nature, scope and legality" of the company's business and operations. According to the plaintiffs, Herbalife and its executives, including CEO Michael Johnson, misrepresented Herbalife as a legitimate multi-level marketing company when it "is actually an illegal pyramid scheme." The court concluded that the suit's plaintiffs have not adequately pled loss causation, meaning that the court need not consider Herbalifeís alternative arguments, according to a court filing. Shares of Herbalife are up 3% in pre-market trading after the court dismissal was widely reported by Bloomberg last night.
07:13 EDTTEVATeva volatility elevated, shares near four year high
Subscribe for More Information
07:13 EDTHLFHerbalife complaint letter signer subpoenaed, Hartford Courant reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use